Benlysta

RSS

belimumab

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Benlysta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Benlysta.

For practical information about using Benlysta, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 22/07/2019

Authorisation details

Product details
Name
Benlysta
Agency product number
EMEA/H/C/002015
Active substance
belimumab
International non-proprietary name (INN) or common name
belimumab
Therapeutic area (MeSH)
Lupus Erythematosus, Systemic
Anatomical therapeutic chemical (ATC) code
L04AA26
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
GlaxoSmithKline (Ireland) Limited
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
13/07/2011
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland

Product information

01/07/2019 Benlysta - EMEA/H/C/002015 - II/0065

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Benlysta is indicated as add-on therapy in adult patients with active, auto-antibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy (see section 5.1).

Assessment history

How useful was this page?

Add your rating
Average
1 rating